

 Early Warning System

IFC-49198

AHB



Quick Facts

Countries	China
Financial Institutions	International Finance Corporation (IFC)
Status	Proposed
Bank Risk Rating	B
Borrower	Anhui Huaheng Biotechnology Co.,Ltd
Sectors	Industry and Trade
Investment Type(s)	Loan
Investment Amount (USD)	\$ 70.50 million
Project Cost (USD)	\$ 105.00 million



Project Description

According to the Bank's website, IFC is proposing to provide up to RMB 500 million (equivalent to US\$70.5 million) in the form of a Green Loan (the Loan) to Qinhuangdao Huaheng Bioengineering Co., Ltd. (QHB), a wholly-owned subsidiary of Anhui Huaheng Biotechnology Co., Ltd. (AHB). The IFC proceeds will be used to fund the capex and working capital needs of malic acid and L-Tryptophan production (the Project).



Early Warning System Project Analysis

This is a Category B project according to IFC's Policy on Environmental and Social Sustainability (2012). Key E&S issues associated with this Project include: 1) AHB's management and monitoring systems to assess and manage E&S risks and impacts from its operations, as well as those related to the supply chains for the facilities covered under the project; 2) management and monitoring of air emissions, wastewater, and hazardous wastes and materials; 3) consistent management of labor and working conditions including occupational health and safety; 4) energy and resource efficiency measures; 5) life and fire safety (LFS) and emergency preparedness and response (EPR) management; 6) AHB's stakeholder engagement activities related to E&S aspects.



Investment Description

- International Finance Corporation (IFC)

The total Project is estimated to cost approximately US\$105 million, among which IFC will finance up to RMB 500 million (equivalent to US\$70.5 million) in the form of a Green Loan, and the remaining will be covered by the Company's internal cash.



Private Actors Description

Anhui Huaheng Biotechnology Co., Ltd. (AHB) is a leading manufacturer of amino acids and other bio-based products in the People's Republic of China (PRC).

Qinhuangdao Huaheng Bioengineering Co., Ltd. is a wholly-owned subsidiary of AHB.

Ms. GUO Henghua is the Founder and Chairwoman of AHB, holding a stake of 27.15%. The remaining shares are held by individuals, institutional investors and other investors from public market, with each representing less than 5% of the shareholding of AHB.



Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	Anhui Huaheng Biotechnology Co., Ltd.	Client	-
-	-	-	-	Qinhuangdao Huaheng Bioengineering Co., Ltd.	Subsidiary	-



Contact Information

Qinhuangdao Huaheng Bioengineering Co., Ltd.

Mr. Wu Xu

General Manager

+86-152-554-73767

xw@ehuaheng.com

18 Shenshan Road, Shan Haiguan District, Qinhuangdao, Hebei Province, PRC

Website www.huahengbio.com

ACCESS TO INFORMATION

You can submit a request for information disclosure at: <https://disclosures.ifc.org/#/inquiries>

If you believe that your request for information from IFC has been unreasonably denied, or that this Policy has been interpreted incorrectly, you can submit a complaint at the link above to IFC's Access to Information Policy Advisor, who reports directly to IFC's Executive Vice President.

ACCOUNTABILITY MECHANISM OF IFC/MIGA

The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org You can learn more about the CAO and how to file a complaint at <http://www.cao-ombudsman.org>



Bank Documents

- [Environmental & Social Review Summary \(ESRS\)](#)